Published in J Exp Med on August 16, 1999
Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest (2004) 3.39
HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A (2001) 2.54
Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A (2003) 2.31
How I treat EBV lymphoproliferation. Blood (2009) 2.18
Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci (2001) 1.89
Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn (2008) 1.82
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood (2006) 1.75
Immune control of the number and reactivation phenotype of cells latently infected with a gammaherpesvirus. J Virol (2002) 1.74
EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol (2003) 1.70
Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev (2010) 1.68
Establishment and maintenance of gammaherpesvirus latency are independent of infective dose and route of infection. J Virol (2003) 1.67
A multifactorial role for P. falciparum malaria in endemic Burkitt's lymphoma pathogenesis. PLoS Pathog (2014) 1.58
Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med (2006) 1.57
Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci U S A (2000) 1.56
Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol (2000) 1.55
Molecular virology of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci (2001) 1.54
EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J Clin Invest (2001) 1.53
Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood (2007) 1.50
Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol (2001) 1.45
Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event. Blood (2015) 1.44
Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1. Proc Natl Acad Sci U S A (2001) 1.40
T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol (2012) 1.36
Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol (2004) 1.36
Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol (2003) 1.36
CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol (2001) 1.35
Potential selection of LMP1 variants in nasopharyngeal carcinoma. J Virol (2004) 1.34
Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death. J Virol (2001) 1.34
Upregulation of xCT by KSHV-encoded microRNAs facilitates KSHV dissemination and persistence in an environment of oxidative stress. PLoS Pathog (2010) 1.30
Serological diagnosis of Epstein-Barr virus infection: Problems and solutions. World J Virol (2012) 1.26
CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis. Autoimmune Dis (2012) 1.20
Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol (2009) 1.16
Role of B-cell proliferation in the establishment of gammaherpesvirus latency. J Virol (2005) 1.15
K13 blocks KSHV lytic replication and deregulates vIL6 and hIL6 expression: a model of lytic replication induced clonal selection in viral oncogenesis. PLoS One (2007) 1.11
BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res (2012) 1.10
Epstein-barr virus coinfection in cerebrospinal fluid is associated with increased mortality in Malawian adults with bacterial meningitis. J Infect Dis (2011) 1.04
Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH. Blood (2010) 1.03
Identification of spliced gammaherpesvirus 68 LANA and v-cyclin transcripts and analysis of their expression in vivo during latent infection. J Virol (2006) 1.01
The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood (2016) 0.99
Epstein-Barr virus infection of Langerhans cell precursors as a mechanism of oral epithelial entry, persistence, and reactivation. J Virol (2007) 0.98
Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies. Adv Hematol (2011) 0.98
Establishment and maintenance of long-term murine gammaherpesvirus 68 latency in B cells in the absence of CD40. J Virol (2005) 0.96
Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa. Dig Dis Sci (2012) 0.94
Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity. Microbes Infect (2010) 0.94
T-cell memory: lessons from Epstein-Barr virus infection in man. Philos Trans R Soc Lond B Biol Sci (2000) 0.92
Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy. Clin Transl Immunology (2014) 0.92
EBV finds a polycomb-mediated, epigenetic solution to the problem of oncogenic stress responses triggered by infection. Front Genet (2013) 0.91
Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. Antiviral Res (2012) 0.88
Epstein-barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity. J Virol (2006) 0.87
Prospective evaluation of epstein-barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy. J Clin Immunol (2010) 0.87
Epstein-Barr virus latent membrane protein 2A preferentially signals through the Src family kinase Lyn. J Virol (2008) 0.87
Detection of Epstein-Barr virus genomes in peripheral blood B cells from solid-organ transplant recipients by fluorescence in situ hybridization. J Clin Microbiol (2002) 0.86
Primary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells. J Virol (2007) 0.86
Cellular immune therapy for viral infections in transplant patients. Indian J Med Res (2013) 0.86
Sequential use of paraformaldehyde and methanol as optimal conditions for the direct quantification of ZEBRA and rta antigens by flow cytometry. Clin Diagn Lab Immunol (2000) 0.85
EBV microRNA BART 18-5p targets MAP3K2 to facilitate persistence in vivo by inhibiting viral replication in B cells. Proc Natl Acad Sci U S A (2014) 0.84
The Role of Gammaherpesviruses in Cancer Pathogenesis. Pathogens (2016) 0.83
Regulation of human cytomegalovirus transcription in latency: beyond the major immediate-early promoter. Viruses (2013) 0.83
X-box binding protein 1 induces the expression of the lytic cycle transactivator of Kaposi's sarcoma-associated herpesvirus but not Epstein-Barr virus in co-infected primary effusion lymphoma. J Gen Virol (2010) 0.83
Pediatric solid-organ transplant recipients carry chronic loads of Epstein-Barr virus exclusively in the immunoglobulin D-negative B-cell compartment. J Clin Microbiol (2001) 0.82
EBV Persistence-Introducing the Virus. Curr Top Microbiol Immunol (2015) 0.82
A Gene Expression Signature That Correlates with CD8+ T Cell Expansion in Acute EBV Infection. J Immunol (2015) 0.82
Structural and functional characterization of a complex between the acidic transactivation domain of EBNA2 and the Tfb1/p62 subunit of TFIIH. PLoS Pathog (2014) 0.81
Therapeutic options in post-transplant lymphoproliferative disorders. Ther Adv Hematol (2011) 0.81
Latent Epstein-Barr virus can inhibit apoptosis in B cells by blocking the induction of NOXA expression. PLoS One (2011) 0.80
Epstein-Barr virus infection in paediatric liver transplant recipients: detection of the virus in post-transplant tonsillectomy specimens. Mol Pathol (2001) 0.80
Evaluation of the risk of lymphomagenesis in xenografts by the PCR-based detection of EBV BamHI W region in patient cancer specimens. Oncotarget (2016) 0.80
Surface immunoglobulin-deficient Epstein-Barr virus-infected B cells in the peripheral blood of pediatric solid-organ transplant recipients. J Clin Microbiol (2004) 0.79
Immunotherapy for epstein-barr virus-related lymphomas. Mediterr J Hematol Infect Dis (2009) 0.79
Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. Exp Mol Med (2015) 0.78
The infectious kiss: newly infected B cells deliver Epstein-Barr virus to epithelial cells. Proc Natl Acad Sci U S A (2006) 0.78
Diametrically opposed effects of hypoxia and oxidative stress on two viral transactivators. Virol J (2010) 0.78
The role of neutralizing antibodies for mouse mammary tumor virus transmission and mammary cancer development. Proc Natl Acad Sci U S A (2002) 0.78
Healthy rabbits are susceptible to Epstein-Barr virus infection and infected cells proliferate in immunosuppressed animals. Virol J (2015) 0.78
Variable EBV DNA load distributions and heterogeneous EBV mRNA expression patterns in the circulation of solid organ versus stem cell transplant recipients. Clin Dev Immunol (2012) 0.77
Epstein-barr virus related lymphoproliferations after stem cell transplantation. Mediterr J Hematol Infect Dis (2009) 0.76
BAFF receptor deficiency limits gammaherpesvirus infection. J Virol (2014) 0.76
EBV Chronic Infections. Mediterr J Hematol Infect Dis (2010) 0.76
Epstein-Barr virus infection transforms CD25+ B cells into antibody-secreting cells in rheumatoid arthritis patients. Immunology (2013) 0.75
Status of Epstein-Barr Virus Coinfection with Helicobacter pylori in Gastric Cancer. J Oncol (2017) 0.75
Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens. Update Cancer Ther (2008) 0.75
A Rapid Embryonic Stem Cell-Based Mouse Model for B-cell Lymphomas Driven by Epstein-Barr Virus Protein LMP1. Cancer Immunol Res (2015) 0.75
Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma. Cancer Immunol Res (2015) 0.75
CD8+ T cell evasion mandates CD4+ T cell control of chronic gamma-herpesvirus infection. PLoS Pathog (2017) 0.75
Asymptomatic primary infection with Epstein-Barr virus: observations on young adult cases. J Virol (2017) 0.75
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
EBV persistence in memory B cells in vivo. Immunity (1998) 4.44
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol (1994) 4.08
Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid. J Virol (1976) 3.33
A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell (1995) 3.17
Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol (1992) 2.95
Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol (1997) 2.53
A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol (1995) 2.28
A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer (1985) 2.23
Is EBV persistence in vivo a model for B cell homeostasis? Immunity (1996) 1.94
Detection of the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy individuals. J Virol (1996) 1.92
Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev (1995) 1.90
Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood (1995) 1.73
Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J Virol (1995) 1.57
Detection of Epstein-Barr virus by polymerase chain reaction. J Clin Microbiol (1990) 1.57
In vitro analysis of the Epstein-Barr virus: host balance in long-term renal allograft recipients. Int J Cancer (1985) 1.55
Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth. Int J Cancer (1987) 1.48
Circulating Epstein-Barr virus-carrying B cells in acute malaria. Lancet (1991) 1.35
Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation (1995) 1.28
Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift. J Virol (1997) 1.25
A simple reverse transcriptase PCR assay to distinguish EBNA1 gene transcripts associated with type I and II latency from those arising during induction of the viral lytic cycle. J Virol (1996) 1.03
EBV gene expression, EBNA antibody responses and EBV+ peripheral blood lymphocytes in post-transplant lymphoproliferative disease. Leuk Lymphoma (1994) 1.01
Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. Transplant Proc (1995) 0.96
Immunocytochemical detection of Epstein-Barr virus antigens in peripheral B lymphocytes after renal transplantation. Transplantation (1995) 0.91
Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J Virol (1985) 4.76
EBV persistence in memory B cells in vivo. Immunity (1998) 4.44
Early events in Epstein-Barr virus infection provide a model for B cell activation. J Exp Med (1985) 3.19
A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell (1995) 3.17
The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients. J Exp Med (1996) 2.67
BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus. J Immunol (1985) 2.66
Suppression of in vitro Epstein-Barr virus infection. A new role for adult human T lymphocytes. J Exp Med (1977) 2.65
Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc Natl Acad Sci U S A (1980) 2.59
Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol (1997) 2.53
Anomalous ABO phenotype in a child after an ABO-incompatible liver transplantation. N Engl J Med (1992) 2.36
The activation antigen BLAST-2, when shed, is an autocrine BCGF for normal and transformed B cells. EMBO J (1987) 2.16
B cell activation and the establishment of Epstein-Barr virus latency. J Exp Med (1988) 2.00
The milk alkali syndrome: a study of the acute disorder with comments on the development of the chronic condition. Medicine (Baltimore) (1965) 1.97
Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell (1982) 1.95
Is EBV persistence in vivo a model for B cell homeostasis? Immunity (1996) 1.94
All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J Virol (1993) 1.92
Detection of the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy individuals. J Virol (1996) 1.92
Polypeptides of the Epstein-Barr virus membrane antigen complex. J Virol (1979) 1.86
Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity (2001) 1.75
When Epstein-Barr virus persistently infects B-cell lines, it frequently integrates. J Virol (1991) 1.70
Epstein-Barr virus membrane antigens: characterization, distribution, and strain differences. J Virol (1981) 1.70
Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol (1982) 1.69
Comparative activity of immunofluorescent antibody and complement-fixing antibody in cytomegalovirus infection. J Clin Microbiol (1976) 1.64
Clinical manifestations of renal allograft derived primary cytomegalovirus infection. Am J Dis Child (1977) 1.60
Cross-reactivity between herpes simplex virus glycoprotein B and a 63,000-dalton varicella-zoster virus envelope glycoprotein. J Virol (1985) 1.56
Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci U S A (2000) 1.56
Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol (2000) 1.55
How much do immigration and trade affect labor market outcomes? Brookings Pap Econ Act (1997) 1.52
Localization of the major NF-kappaB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs. J Biol Chem (1997) 1.51
Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother (2000) 1.50
EBV persistence involves strict selection of latently infected B cells. J Immunol (2000) 1.50
Characterization of cross-reacting antigens on the Epstein-Barr virus envelope and plasma membranes of producer cells. Cell (1979) 1.48
An extracorporeal complexing hemodialysis system for the treatment of methylmercury poisoning. I. In vitro studies of the effects of four complexing agents on the distribution and dialyzability of methylmercury in human blood. J Pharmacol Exp Ther (1975) 1.48
Transesophageal echocardiography reveals an unusual cause of hemodynamic collapse during orthotopic liver transplantation--two case reports. Transplantation (1995) 1.42
Synthesis and processing of the three major envelope glycoproteins of Epstein-Barr virus. J Virol (1983) 1.41
Utility is not just posttransplant outcome! Am J Transplant (2006) 1.40
Erythrocyte adenosine triphosphate depletion during hypophosphatemia in a uremic subject. N Engl J Med (1969) 1.35
The prototypical Epstein-Barr virus-transformed lymphoblastoid cell line IB4 is an unusual variant containing integrated but no episomal viral DNA. J Virol (1991) 1.31
Expression of the Blast-1 activation/adhesion molecule and its identification as CD48. J Immunol (1991) 1.30
Fetal cells participate over time in the response to specific types of murine maternal hepatic injury. Hum Reprod (2006) 1.30
Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein. Proc Natl Acad Sci U S A (1987) 1.28
Long-term therapy for chronic bacteriuria in men. U.S. Public Health Service cooperative study. Ann Intern Med (1975) 1.28
Studies on the location and orientation of proteins in the sarcoplasmic reticulum. Eur J Biochem (1973) 1.27
A regional end-stage renal disease program: twelve years' experience. Ann Intern Med (1980) 1.23
Differential effect of phosphonoacetic acid on the expression of Epstein-Barr viral antigens and virus production. Proc Natl Acad Sci U S A (1976) 1.22
The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell. J Immunol (1980) 1.17
An Epstein-Barr virus-associated superantigen. J Exp Med (1996) 1.17
Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis. Transplantation (2001) 1.16
An analysis of cytomegalovirus infection and HLA antigen matching on the outcome of renal transplantation. Ann Surg (1978) 1.15
Biochemical analysis suggests distinct functional roles for the BLAST-1 and BLAST-2 antigens. J Immunol (1986) 1.15
Varicella-zoster virus envelope glycoproteins: biochemical characterization and identification in clinical material. Virology (1985) 1.14
Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity. AJR Am J Roentgenol (1996) 1.14
Prevention of recurrent bacteriuria with continuous chemotherapy. Ann Intern Med (1968) 1.13
ASTS recommended practice guidelines for controlled donation after cardiac death organ procurement and transplantation. Am J Transplant (2009) 1.13
Liver transplantation for primary hepatic cancer. Transplantation (1992) 1.13
The ontogeny of brain lateralization for speech and nonspeech stimuli. Brain Lang (1975) 1.11
Histoplasmosis with hypercalcemia, renal failure, and papillary necrosis. Confusion with sarcoidosis.. JAMA (1977) 1.11
Blast-1 possesses a glycosyl-phosphatidylinositol (GPI) membrane anchor, is related to LFA-3 and OX-45, and maps to chromosome 1q21-23. J Exp Med (1989) 1.11
Transmission of cytomegalovirus infection with renal allograft. Kidney Int (1975) 1.08
Processing of the Epstein-Barr virus-encoded latent membrane protein p63/LMP. J Virol (1990) 1.07
A virus-free immunogen effective against Epstein-Barr virus. Nature (1979) 1.06
The reactivity of the thiol groups of the adenosine triphosphatase of sarcoplasmic reticulum and their location on tryptic fragments of the molecule. Biochem J (1977) 1.06
Analysis of cellular immune response to EBV by using cloned T cell lines. J Immunol (1983) 1.05
Insulin action and binding in isolated hepatocytes from fasted, streptozotocin-diabetic, and older, spontaneously obese rats. Biochem J (1980) 1.05
Dialysance studies of varied solutes and biochemical changes during hemodialysis. Trans Am Soc Artif Intern Organs (1964) 1.03
Renal function before and after unilateral nephrectomy in renal donors. Kidney Int (1975) 1.03
Liver transplant candidate stratification systems. Implications for third-party payors and organ allocation. Transplantation (1994) 1.02
Hepatic retransplantation in New England--a regional experience and survival model. Transplantation (1993) 1.01
Reversible inhibition by phosphonoacetic acid of human B lymphocyte transformation by Epstein-Barr virus. Virology (1978) 1.00
Biochemical, genetic, and functional analyses of the phosphorylation sites on the Epstein-Barr virus-encoded oncogenic latent membrane protein LMP-1. J Virol (1993) 0.99
Molecular cloning of the lymphocyte activation marker Blast-1. EMBO J (1987) 0.99
A virtual look at Epstein-Barr virus infection: simulation mechanism. J Theor Biol (2008) 0.97
Conduction velocity groups in the cat's optic nerve classified according to their retinal origin. Exp Brain Res (1971) 0.97
Toxicity following methoxyflurane anesthesia. II. Fluoride concentrations in nephrotoxicity. JAMA (1970) 0.97
Separation and characterisation of tryptic fragments from the adenosine triphosphatase of sarcoplasmic reticulum. Eur J Biochem (1975) 0.97
Epstein-Barr virus antigens-a challenge to modern biochemistry. Adv Cancer Res (1982) 0.97
A verbal long term memory deficit in frontal lobe damaged patients. Cortex (1986) 0.96
Surface antigen changes during B-lymphocyte activation in primates. Cell Immunol (1984) 0.95
An 88,000-Mr Giardia lamblia surface protein which is immunogenic in humans. Infect Immun (1986) 0.94
Multiple organ failure after liver transplantation. Crit Care Med (1995) 0.94
Influenza vaccination of patients with glomerular diseases. Effects on creatinine clearance, urinary protein excretion, and antibody response. Ann Intern Med (1974) 0.93
Stimulus for organ donation: a survey of the American Society of Transplant Surgeons membership. Am J Transplant (2009) 0.93
Pharyngeal wall cancer: an analysis of treatment results complications and patterns of failure. Int J Radiat Oncol Biol Phys (1979) 0.93
Antibody response to influenza vaccination in renal transplant patients: correlation with allograft function. Ann Intern Med (1976) 0.93
Effects of furosemide on low-dose mercuric chloride acute renal failure in the rat. Kidney Int (1975) 0.92
The labour-market consequences of generational crowding. Eur J Popul (1988) 0.91
Neuronal responses in the visual cortex of awake cats to stationary and moving targets. Exp Brain Res (1971) 0.90
Binocular interaction in the visual cortex of awake cats. Exp Brain Res (1971) 0.90
Results of conservation surgery for cancers of the supraglottis and pyriform sinus. Laryngoscope (1980) 0.90
Characterization of the CD48 gene demonstrates a positive element that is specific to Epstein-Barr virus-immortalized B-cell lines and contains an essential NF-kappa B site. J Virol (1995) 0.88
CD48 binds to heparan sulfate on the surface of epithelial cells. J Biol Chem (1998) 0.88
The criterion of relevance. Am J Public Health Nations Health (1967) 0.87
A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation (1996) 0.86
A ligand for human CD48 on epithelial cells. J Immunol (1997) 0.86
Induction of insulin resistance in normal adipose tissue by uremic human serum. Kidney Int (1984) 0.86
It is time to re-think 'extended criteria'. Am J Transplant (2006) 0.84